Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Tisagenlecleucel Approved in Europe for Relapsed/Refractory Follicular Lymphoma

May 17th 2022

The European Commission has approved the CD19-targeting chimeric antigen receptor T-cell agent tisagenlecleucel for the treatment of adults with relapsed/refractory follicular lymphoma following at least 2 lines of systemic therapy.

Finding the Underlying Mutations Driving CAR-T Failure

May 17th 2022

New research illuminates the mechanisms that make B-cell lymphomas resistant to important immunotherapy

New Treatment Options Are in Play for Relapsed/ Refractory DLBCL

May 12th 2022

Up to 40% of patients with diffuse large B-cell lymphoma are refractory to or relapse after first-line treatment.

Dr. Westin on the Evolving Landscape of CAR T-Cell Therapy in NHL

May 3rd 2022

Jason R. Westin, MD, discusses the evolving landscape of CAR T-cell therapy in non-Hodgkin lymphoma.

Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCL

May 3rd 2022

Lori A. Leslie, MD, reviews how the approval of axicabtagene ciloleucel may impact or enhance current practice patterns for adult patients with large B-cell lymphoma.

Very Low Dose Radiation Therapy Demonstrates Efficacy in Indolent Non-Hodgkin Lymphoma

May 2nd 2022

Although it is not considered to be a standard of care for patients with indolent non-Hodgkin lymphoma, very low dose radiation therapy was found to have efficacy in the palliative setting and to allow for retreatment to the same field when needed.

CAR NK Cell Therapies Show Preliminary Safety and Efficacy in AML, Non-Hodgkin Lymphoma

April 25th 2022

The novel allogeneic CAR-engineered natural killer cell therapies, NKX101 and NKX01, showcased early signs of safety and efficacy when utilized in the treatment of heavily pretreated patients with acute myeloid leukemia and non-Hodgkin lymphoma.

Mosunetuzumab Approaches EU Approval for Relapsed or Refractory Follicular Lymphoma

April 25th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval under conditional marketing authorization for mosunetuzumab for use in adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 therapies.

Match-Adjusted Comparison Shows Comparable Efficacy Outcomes for Axi-cel and Tisa-cel in Follicular Lymphoma

April 25th 2022

Results of a match-adjusted analysis of patients with follicular lymphoma treated with axicabtagene ciloleucel in ZUMA-5 trial vs those treated with tisagenlecleucel in ELARA showed a similar efficacy profile between the 2 cellular therapies.

FDA Grants Fast Track Designation to ADI-001 in Relapsed/Refractory Non-Hodgkin Lymphoma

April 20th 2022

The FDA has granted a fast track designation to the CAR T-cell therapy ADI-001 for the treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Bortezomib Improves OS in Newly Diagnosed T-Cell Lymphoblastic Leukemia and Lymphoma

April 18th 2022

The addition of bortezomib to chemotherapy improved survival rates in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma, according to data from the phase 3 AALL1231 trial.

Epcoritamab Elicits 63.1% ORR in Relapsed/Refractory Large B-cell Lymphoma

April 14th 2022

Epcoritamab was found to produce an encouraging overall response rate in patients with relapsed or refractory large B-cell lymphoma who previously received CAR T-cell therapy.

T-Cell Attributes of Axi-cel Linked to Outcomes in LBCL

April 10th 2022

The T-cell attributes of axicabtagene ciloleucel impacted tumor burden, efficacy outcomes, peak levels of proinflammatory cytokines, and toxicities such as neurologic events and cytokine release syndrome in patients with relapsed/refractory large B-cell lymphoma.

NK Cells Plus Bispecific Antibody Delivers Strong Results in Advanced Lymphoma

April 10th 2022

The innate cell engager AMF13 combined with preactivated and expanded natural killer (NK) cells induced “very encouraging activity” in patients with heavily pretreated lymphoma.

Movement of Novel Agents Up Front Is Current Focus in Hematologic Cancers

April 6th 2022

Ann S. LaCasce, MD, MMSc, discusses updates in lymphoma, myelofibrosis, and chronic lymphocytic leukemia.

FDA Approves Axicabtagene Ciloleucel for Second-Line LBCL

April 1st 2022

The FDA has approved axicabtagene ciloleucel for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.

Lisocabtagene Maraleucel sNDA for Second-Line Relapsed/Refractory LBCL Accepted for Review in Japan

March 26th 2022

The Ministry of Health, Labour, and Welfare has accepted a supplemental new drug application for lisocabtagene maraleucel for the second-line treatment of patients with relapsed or refractory large B-cell lymphoma.

FDA Discourages Pursuit of Marketing Authorization for Zandelisib in MZL, Follicular Lymphoma

March 25th 2022

The FDA has discouraged the pursuit of a marketing authorization of the PI3K inhibitor zandelisib in patients with follicular lymphoma or marginal zone lymphoma, citing the need for randomized trial data.

Polatuzumab Vedotin Plus R-CHP Recommended for EU Approval for Previously Untreated DLBCL

March 25th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion in favor of the approval of polatuzumab vedotin for use in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone in patients with previously untreated diffuse large B-cell lymphoma.

Tisagenlecleucel Approaches EU Approval for Relapsed/Refractory Follicular Lymphoma

March 25th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of tisagenlecleucel for use in adult patients with relapsed/refractory follicular lymphoma following 2 lines of systemic treatment.